Evidence map›Paper›PMID 36693761›Full record

ArticleRNA (New York, N.Y.)2023

Programmable macromolecule-based RNA-targeting therapies to treat human neurological disorders.

Kathryn H Morelli, Aaron A Smargon, Gene W Yeo

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RNA (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kathryn H MorelliDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California 92093, USA.
Aaron A SmargonDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California 92093, USA.
Gene W YeoDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California 92093, USA geneyeo@ucsd.edu.ORCID 0000-0002-0799-6037
University of California San Diego · US

Funding

Functional RNA elements in the human genomeR01HG004659 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Kevin Daniel Corbett, Eugene Wei-Ming Yeo · 2008 to 2026
$12.4M
Therapeutic strategies for microsatellite expansion diseases using RNA-targeting CRISPR/CasR01NS103172 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MAURICE SCOTT SWANSON, Eugene Wei-Ming Yeo · 2017 to 2026
$5.6M
Development of RNA-Directed Therapeutics for Myotonic Dystrophy Type 1 NeuropathologyF32NS112654 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MORELLI, KATHRYN H · 2019 to 2021
$161k
NHGRI NIH HHS R01 HG004659NINDS NIH HHS F32 NS112654NINDS NIH HHS R01 NS103172
6 · The paper itself

Abstract

Disruptions in RNA processing play critical roles in the pathogenesis of neurological diseases. In this Perspective, we discuss recent progress in the development of RNA-targeting therapeutic modalities. We focus on progress, limitations, and opportunities in a new generation of therapies engineered from RNA binding proteins and other endogenous RNA regulatory macromolecules to treat human neurological disorders.

Indexed as

Nervous System DiseasesRNAHumansRNA Processing, Post-TranscriptionalRNAgene therapyneurological disordersprogrammable macromoleculesRNA-targeting therapeutics

Identifiers

PMID36693761
PMCPMC10019361
OpenAlexW4317859963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.